NCT05056558View on ClinicalTrials.gov

Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

PHASE3UnknownINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

October 31, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

September 30, 2022

Conditions
Covid19
Interventions
DRUG

Baricitinib

Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14

DRUG

Placebo

Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14

Trial Locations (1)

Unknown

Dhaka Medical College, Mugda Medical College, Kuwait Bangladesh Friendship Government Hospital, Dhaka

Sponsors
All Listed Sponsors
lead

Incepta Pharmaceuticals Ltd

INDUSTRY